For women, a reproductive cancer diagnosis can be devastating, initially. Here at the Women’s Cancer Research Foundation, we offer hope to women through access to new more promising cancer treatments via clinical trial participation.
We strive to find the newest and most effective cancer treatments, having developed collaborative relationships with prominent pharmaceutical and biotech companies, including: Merck, Amgen, Eli Lilly, Genentech-Roche, Pfizer, Endocyte, Centocor Ortho Biotech, Nektar Therapeutics, Abbott Laboratories and Sunesis Pharmaceuticals, Inc. The Women’s Cancer Research Foundation emphasizes offering Phase II and Phase III clinical trials to women afflicted with breast and gynecologic (endometrial, uterine and ovarian) cancer.
Additionally, the Women’s Cancer Research Foundation emphasizes publishing the results of our clinical trial research. We are nearing 100 publications in our eleventh year, 16 publications in 2010 alone. The Women’s Cancer Research Foundation is a 501(c)(3) tax-exempt non-profit organization.
